Triple-negative breast cancer trials recruiting in Massachusetts

All Triple-negative breast cancer trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
  NCT06908928 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• A Study of LY4175408 in Participants With Advanced Cancer
  NCT07046923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
  NCT04434040 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
  NCT06562192 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Massachusetts: Boston
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Foxborough, Milford, South Weymouth
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Danvers, Newton
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Foxborough, Methuen, Milford
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Massachusetts: Boston
• This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
  NCT06451497 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston